{"slug":"radiopharmaceuticals","as_of":"2026-10-22","verified_at":"2026-10-22","languages":{"zh":{"title":"台灣核醫藥物公司與管線總表","summary":[{"text":"截至2026年10月22日，本表收錄2家有可核對核醫藥物臨床管線的台灣公司：吉晟與禾榮科。","source_urls":["https://www.petpharmbio.com/products-20?lang=tw","https://clinicaltrials.gov/api/v2/studies/NCT07691775"]},{"text":"吉晟所列[161Tb] PSMA I&T為mCRPC一期管線，禾榮科F18 FBPA的實體腫瘤影像試驗則登錄為一期／二期、招募中。","source_urls":["https://www.petpharmbio.com/products-20?lang=tw","https://clinicaltrials.gov/api/v2/studies/NCT07691775"]}],"undisclosed":"本表不是全台核醫公司總數；未取得可核對公開階段的其他候選公司不列入，也未填補吉晟此試驗的結果或核准日。"},"en":{"title":"Taiwan Radiopharmaceutical Companies and Pipelines","summary":[{"text":"As of October 22, 2026, this table includes 2 Taiwan companies with verified clinical radiopharmaceutical programs: PET Pharm Biotech and Heron Neutron Medical.","source_urls":["https://www.petpharmbio.com/products-20?lang=tw","https://clinicaltrials.gov/api/v2/studies/NCT07691775"]},{"text":"The selected [161Tb] PSMA I&T program is Phase 1 for mCRPC; Heron’s F18 FBPA solid-tumor imaging trial is registered as Phase 1/2 and recruiting.","source_urls":["https://www.petpharmbio.com/products-20?lang=tw","https://clinicaltrials.gov/api/v2/studies/NCT07691775"]}],"undisclosed":"This is not the total number of Taiwan radiopharmaceutical companies. Other candidates without a verified public stage are excluded; trial results and an approval date for this program remain unfilled."}},"companies":[{"company":"吉晟生","company_en":"PET Pharm Biotech","ticker":"7762","product":"[161Tb] PSMA I&T（PPhB-Tb01）","product_en":"[161Tb] PSMA I&T (PPhB-Tb01)","indication":"轉移性去勢抗性前列腺癌（mCRPC）","indication_en":"Metastatic castration-resistant prostate cancer (mCRPC)","stage":"第 1 期臨床試驗","stage_en":"Phase 1","as_of":"2026-10-22","source":"https://www.petpharmbio.com/products-20?lang=tw","quote":"[¹⁶¹Tb] PSMA I&T — Phase 1","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R","company_quote":"吉晟生技股份有限公司","catalyst":null,"date_basis":"現行公司管線頁無發布日；as_of為查核日。"},{"company":"禾榮科","company_en":"Heron Neutron Medical","ticker":"7799","product":"F18 FBPA（HN-FBPA-001）","product_en":"F18 FBPA (HN-FBPA-001)","indication":"實體腫瘤PET／CT影像診斷","indication_en":"PET/CT diagnostic imaging of solid tumors","stage":"第1/2期；招募中","stage_en":"Phase 1/2; recruiting","as_of":"2026-07-09","source":"https://clinicaltrials.gov/api/v2/studies/NCT07691775","quote":"RECRUITING","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"禾榮科技股份有限公司","catalyst":null}],"scope":{"not_exhaustive":true,"coverage":"Source-verified selection from existing Taiwan company profiles; one row per company, with one named program or service selected for that company.","stage_basis":"Stage is the statement in the cited source as of its stated date; an undated live page uses the access date. Development, trial authorization, recruitment and marketing authorization remain separate.","count_basis":"Company rows, not an industry-wide census or a count of independent drugs. Licensed products, original development and customer manufacturing are identified in product and stage fields."}}